urea has been researched along with Heart Disease, Ischemic in 21 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We assessed two suggested new inotropic strategies in a clinically relevant pig model of ischemic acute heart failure (AHF): treatment with the myosin activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I)." | 7.88 | Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. ( Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L, 2018) |
| " Therefore, in order to control the heart rate and prevent myocardial ischemia, low dose landiolol was infused prophylactically." | 7.74 | [Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy]. ( Nakagawa, H; Nanba, M; Okayama, Y, 2007) |
| "Landiolol, a highly cardioselective beta1-blocker, has cardioprotective effects against ischemia-reperfusion injury, although the precise mechanism is still unclear." | 7.74 | Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway. ( Hirai, H; Minamiyama, Y; Sakaguchi, M; Sasaki, Y; Shibata, T; Suehiro, S; Takahashi, Y; Takemura, S, 2007) |
| " We assessed two suggested new inotropic strategies in a clinically relevant pig model of ischemic acute heart failure (AHF): treatment with the myosin activator omecamtiv mecarbil (OM) or dobutamine and ivabradine (D+I)." | 3.88 | Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure. ( Bakkehaug, JP; How, OJ; Kildal, AB; Myrmel, T; Rødland, L; Rønning, L, 2018) |
| " Therefore, in order to control the heart rate and prevent myocardial ischemia, low dose landiolol was infused prophylactically." | 3.74 | [Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy]. ( Nakagawa, H; Nanba, M; Okayama, Y, 2007) |
| "Landiolol, a highly cardioselective beta1-blocker, has cardioprotective effects against ischemia-reperfusion injury, although the precise mechanism is still unclear." | 3.74 | Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway. ( Hirai, H; Minamiyama, Y; Sakaguchi, M; Sasaki, Y; Shibata, T; Suehiro, S; Takahashi, Y; Takemura, S, 2007) |
| "Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time." | 2.80 | Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. ( Chen, MM; Chou, W; Eisenberg, P; Escandón, R; Greenberg, BH; Lee, JH; Malik, FI; Megreladze, I; Saikali, KG; Shaburishvili, T; Treshkur, T; Wasserman, SM; Wolff, AA, 2015) |
| "Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT." | 2.79 | A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischem ( Hara, K; Hirano, M; Iino, M; Ikari, Y; Jinzaki, M; Kuribayashi, S; Tanimoto, M; Yamaguchi, T; Yamashina, A, 2014) |
| "Landiolol hydrochloride is an intravenous β1-blocker with a very short half-life." | 2.78 | Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan. ( Hamada, C; Hara, K; Hirano, M; Iino, M; Ikari, Y; Jinzaki, M; Kuribayashi, S, 2013) |
| "Esmolol also has been used for treatment of perioperative hypertension and for reducing cardiac work in patients with ischemic heart disease." | 2.43 | [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system]. ( Mio, Y, 2006) |
| "In male rats, acute renal failure was simulated by clamping the vascular pedicle of the left kidney for 60 or 90 min and right-sided nephrectomy." | 1.56 | Stimulation of Structural and Functional Recovery of the Kidney in Rats with Postischemic Acute Renal Failure of Different Severity by Embryonic Protein-Peptide Complex Therapy. ( Drozhzheva, VV; Efremov, GD; Golovanov, SA; Kirpatovskii, VI; Samoilova, SI; Sivkov, AV, 2020) |
| "Ischemic arrhythmias are the main causes of sudden cardiac death." | 1.46 | Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes. ( Gui, YJ; Liao, CX; Liu, Q; Peng, R; Wang, M; Xu, DY; Zhao, W; Zhao, X, 2017) |
| "Landiolol is a short-acting beta-blocker, with high beta 1-selectivity and a short duration of action." | 1.35 | Clinical role and efficacy of landiolol in the intensive care unit. ( Akada, S; Hongo, T; Miyagi, Y; Sakamoto, A; Sato, C; Takeda, S; Tanaka, K; Terajima, K; Yoshida, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Rødland, L | 2 |
| Rønning, L | 2 |
| Kildal, AB | 2 |
| Myrmel, T | 2 |
| How, OJ | 2 |
| Kirpatovskii, VI | 1 |
| Sivkov, AV | 1 |
| Golovanov, SA | 1 |
| Drozhzheva, VV | 1 |
| Efremov, GD | 1 |
| Samoilova, SI | 1 |
| Poveda-Jaramillo, R | 1 |
| Monaco, F | 1 |
| Zangrillo, A | 1 |
| Landoni, G | 1 |
| Bakkehaug, JP | 1 |
| Jinzaki, M | 4 |
| Hirano, M | 4 |
| Hara, K | 3 |
| Suzuki, T | 1 |
| Yamashina, A | 2 |
| Ikari, Y | 3 |
| Iino, M | 3 |
| Yamaguchi, T | 2 |
| Kuribayashi, S | 4 |
| Hamada, C | 1 |
| Furuichi, Y | 1 |
| Sakamoto, A | 2 |
| Tanimoto, M | 1 |
| Greenberg, BH | 1 |
| Chou, W | 1 |
| Saikali, KG | 1 |
| Escandón, R | 1 |
| Lee, JH | 1 |
| Chen, MM | 1 |
| Treshkur, T | 1 |
| Megreladze, I | 1 |
| Wasserman, SM | 1 |
| Eisenberg, P | 1 |
| Malik, FI | 1 |
| Wolff, AA | 1 |
| Shaburishvili, T | 1 |
| Kido, T | 2 |
| Mochizuki, T | 1 |
| Yamada, Y | 1 |
| Tanaka, R | 1 |
| Kanzaki, S | 1 |
| Higashi, M | 1 |
| Yoshioka, K | 1 |
| Liu, Q | 1 |
| Zhao, X | 1 |
| Peng, R | 1 |
| Wang, M | 1 |
| Zhao, W | 1 |
| Gui, YJ | 1 |
| Liao, CX | 1 |
| Xu, DY | 1 |
| Suzuki, Y | 1 |
| Morihara, A | 1 |
| Desaki, Y | 1 |
| Terao, K | 1 |
| Semba, K | 1 |
| Takasaki, Y | 1 |
| Jindrich, S | 1 |
| Ondrej, L | 1 |
| Viktor, M | 1 |
| Zbynek, P | 1 |
| Tomas, P | 1 |
| Ladislav, D | 1 |
| Jiri, V | 1 |
| Lenka, S | 1 |
| Miroslav, S | 1 |
| Mantovani, V | 1 |
| Kennergren, C | 1 |
| Bugge, M | 1 |
| Sala, A | 1 |
| Lönnroth, P | 1 |
| Berglin, E | 1 |
| Makhneva, AV | 1 |
| Sviridkina, LP | 1 |
| Toporova, SG | 1 |
| Schroeder, MA | 1 |
| Clarke, K | 1 |
| Neubauer, S | 1 |
| Tyler, DJ | 1 |
| Mio, Y | 1 |
| Nakagawa, H | 1 |
| Nanba, M | 1 |
| Okayama, Y | 1 |
| Takahashi, Y | 1 |
| Takemura, S | 1 |
| Minamiyama, Y | 1 |
| Shibata, T | 1 |
| Hirai, H | 1 |
| Sasaki, Y | 1 |
| Sakaguchi, M | 1 |
| Suehiro, S | 1 |
| Yoshida, Y | 1 |
| Terajima, K | 1 |
| Sato, C | 1 |
| Akada, S | 1 |
| Miyagi, Y | 1 |
| Hongo, T | 1 |
| Takeda, S | 1 |
| Tanaka, K | 1 |
| Palmer, A | 1 |
| Bulpitt, C | 1 |
| Beevers, G | 1 |
| Coles, E | 1 |
| Fletcher, A | 1 |
| Ledingham, J | 1 |
| Petrie, J | 1 |
| Webster, J | 1 |
| Dollery, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of ONO-1101 in Patients Scheduled for Coronary Angiography, a Double-Blind, Randomized,Placebo-Controlled, Parallel Group, Multi-Center Study[NCT00560209] | Phase 2 | 183 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Tolerability and CK-1827452 Plasma Concentrations During Intravenous and Immediate-Release Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina[NCT00682565] | Phase 2 | 94 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00682565)
Timeframe: 1 day
| Intervention | seconds (Mean) |
|---|---|
| Mid Dose Active Drug | 41.5 |
| High Dose Active Drug | 40.5 |
| All Placebo | 60.1 |
"This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B.~Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina." (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 7 |
| All Placebo | 2 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 4 |
| High Dose Active Drug | 2 |
| All Placebo | 1 |
The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 0 |
| All Placebo | 1 |
ST Segment Depression measured by Electrocardiography while performing ETT-3. (NCT00682565)
Timeframe: 1 day
| Intervention | Participants (Number) |
|---|---|
| Mid Dose Active Drug | 0 |
| High Dose Active Drug | 1 |
| All Placebo | 2 |
4 reviews available for urea and Heart Disease, Ischemic
| Article | Year |
|---|---|
Ultra-Short-Acting β-Blockers (Esmolol and Landiolol) in the Perioperative Period and in Critically Ill Patients.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Cardiac S | 2018 |
[Perioperative cardiovascular evaluation and management for noncardiac surgery].
Topics: Adrenergic beta-Antagonists; Anesthesia; Atenolol; Bisoprolol; Fatty Acids, Monounsaturated; Fluvast | 2014 |
Hyperpolarized magnetic resonance: a novel technique for the in vivo assessment of cardiovascular disease.
Topics: Animals; Bicarbonates; Carbon Isotopes; Cardiomyopathies; Cardiovascular Diseases; Diagnostic Techni | 2011 |
[New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiovascular System; Heart Rate; Humans; Mor | 2006 |
5 trials available for urea and Heart Disease, Ischemic
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Chi-Square Distribution; Coronary Angiography; Double- | 2013 |
Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Artifacts; Blood Pressure; Coronary Angiography; Dose- | 2013 |
A multicenter, open-label study of an intravenous short-acting β1-adrenergic receptor antagonist landiolol hydrochloride for coronary computed tomography angiography by 16-slice multi-detector computed tomography in Japanese patients with suspected ischem
Topics: Adrenergic beta-Antagonists; Aged; Coronary Angiography; Female; Heart Rate; Humans; Injections, Int | 2014 |
Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angina Pectoris; Dose-Response Relationship, D | 2015 |
Myocardial metabolism assessed by microdialysis: a prospective randomized study in on- and off-pump coronary bypass surgery.
Topics: Aged; Biomarkers; Coronary Artery Bypass, Off-Pump; Energy Metabolism; Female; Glucose; Glycerol; Hu | 2010 |
12 other studies available for urea and Heart Disease, Ischemic
| Article | Year |
|---|---|
Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Disease Models, Animal; Dobutamine; Drug | 2020 |
Stimulation of Structural and Functional Recovery of the Kidney in Rats with Postischemic Acute Renal Failure of Different Severity by Embryonic Protein-Peptide Complex Therapy.
Topics: Acute Kidney Injury; Animals; Creatinine; Kidney; Male; Myocardial Ischemia; Rats; Regenerative Medi | 2020 |
Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Cardiovascular Agents; Diastole; Dobutamine; Drug Therapy, Combination; | 2018 |
Radiation-Dose-Lowering Effects of Landiolol Hydrochloride in Coronary Angiography Using Computed Tomography (DELIGHT) - A Prospective Multicenter Study.
Topics: Blood Pressure; Coronary Angiography; Heart Rate; Humans; Morpholines; Myocardial Ischemia; Prospect | 2016 |
Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes.
Topics: Animals; Animals, Newborn; Arrhythmias, Cardiac; Benzoates; Cell Survival; Cells, Cultured; Connexin | 2017 |
Successful treatment with landiolol for the recurrence of significant ST-segment depression during early postoperative period.
Topics: Anti-Arrhythmia Agents; Endarterectomy, Carotid; Humans; Male; Middle Aged; Morpholines; Myocardial | 2008 |
The profile and prognosis of patients hospitalised with heart failure. The value of discharge blood pressure amd cholesterol.
Topics: Age Factors; Aged; Blood Pressure; Cholesterol; Chronic Disease; Creatinine; Female; Heart Failure; | 2008 |
[Role of endogenous intoxication in development of involutive and pathologic processes in patients of elderly and senile age with ischemic heart disease].
Topics: Aged; Aged, 80 and over; Aging; Blood Glucose; Female; Humans; L-Lactate Dehydrogenase; Male; Myocar | 2010 |
[Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy].
Topics: Adrenergic beta-Antagonists; Aged; Aortic Valve Stenosis; Gastrectomy; Humans; Male; Morpholines; My | 2007 |
Landiolol has cardioprotective effects against reperfusion injury in the rat heart via the PKCepsilon signaling pathway.
Topics: Adrenergic beta-Antagonists; Alkaloids; Animals; Benzophenanthridines; Cardiotonic Agents; Glyburide | 2007 |
Clinical role and efficacy of landiolol in the intensive care unit.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Blood Pressure; Catecholamines; Female; Hear | 2008 |
Risk factors for ischaemic heart disease and stroke mortality in young and old hypertensive patients.
Topics: Adult; Age Distribution; Aged; Cerebrovascular Disorders; Cholesterol; Female; Humans; Hypertension; | 1995 |